Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
biotech
boston
3
×
boston blog main
life sciences
3
×
boston top stories
clinical trials
gene therapy
national blog main
national top stories
san francisco blog main
alexion pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bioinnovation capital
biolabs
bluebird bio
boehringer ingelheim
chemotherapy
daraprim
deals
dicerna pharmaceuticals
drug pricing
drugs
duchenne muscular dystrophy
dyne therapeutics
eli lilly
epipen
epipens
exome
facioscapulohumeral muscular dystrophy
generic drugs
hepatitis b
indiana blog main
indiana top stories
insulin
johannes fruehauf
What
long
3
×
ago
drug
medicines
abandoning
baggage
biotech
biotechs
companies
considering
cuts
data
deal
development
dicerna
diseases
driving
dyne
early
expected
experimental
eyes
free
genetic
gets
good
having
healthcare
history
humans
improved
industry
innovation
innovations
interference
investment
ipo
ipos
life
medical
Language
unset
Current search:
long
×
photo
×
" life sciences "
×
boston
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M